The House of Representatives voted 332-94 to approve a two-year budget outline Dec. 12 that would cancel $63 billion in sequester cuts for 2014 and 2015—in exchange for extending sequestration through 2023. The Bipartisan Budget Act of 2013 now heads to the Senate, where it is expected to pass next week. President Barack Obama has indicated that he would sign the 77-page bill. “It clears the path for critical investments in things like scientific research, which has the potential to unleash new innovation and new industries,” Obama said in a statement Dec. 10. The bill gives Congress about one month to complete the appropriations process before the current continuing resolution expires Jan. 15. Crafted by Rep. Paul Ryan (R-Wis.) and Sen. Patty Murray (D-Wash.), the deal signals a breakthrough in negotiations for a Congress that has been locked in a series of partisan fiscal fights. The deal represents the first compromise on the nation’s finances through the full appropriations process since April 29, 2009. The measure sets discretionary spending for the current fiscal year at $1.012 trillion—about halfway between each party’s original proposals—a $45 billion increase over the level mandated by the 2011 Budget Control Act. Also, the deal provides the spending cap for 2015, and likely assures that the federal government would remain open through 2015, potentially allowing Congress to finalize the FY 2015 appropriations process before next year’s midterm elections. Thirty-two House Democrats voted against the bill, with many opposed to the lack of an unemployment insurance extension. About 1.3 million Americans will stop receiving checks on Jan. 1, 2014. Also, the measure does nothing to raise the debt ceiling, which needs to be addressed before its Feb. 7 deadline. |
| Click Here to Subscribe and Read the Whole Story |
Bipartisan Deal Eases Some Budget Cuts By Extending Sequestration Through 2023
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Members of the National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs at a recent meeting struggled to define the new group’s the role and raised concerns about some initial growing pains.


Earlier this week, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli), for adults with previously untreated stage 2 or stage 3 rectal cancer that is mismatch repair deficient or microsatellite instability-high, marking a celebratory moment for the field.


Keaton Herzer had never even heard of cholangiocarcinoma when he was diagnosed in 2025.


Neeha Zaidi, MD, is turning the tables on pancreatic cancer. Mutations to a gene called KRAS—a cancer driver common to almost all pancreatic cancers—are now a target for prevention and treatment.
By Valerie Mehl


HHS, through the recently announced Office of Women’s Health, announced taht it will be pursuing a collaboration with the Agency for Healthcare Research and Quality and DenseBreast-info.org to strengthen breast cancer screening, expand breast density education, and improve timely diagnostic follow-up, particularly for midlife women.





